semaglutide chronic kidney disease in patients with overweight or obesity and without diabetes: a randomized double-blind placebo-controlled clinical trial Presented at #ERA24: FLOW trial:

Introduction In the realm of modern medicine, semaglutide has emerged as a groundbreaking solution for weight management and diabetes control

pause or step back a dose for significant GI symptoms, then resume after stabilization

Lose weight with tirzepatide

If you experience persistent nausea at a new dose, the standard medical recommendation is to stay at that dose level (or even drop back to the previous one) for an additional 4 weeks before attempting to increase again

Kohno D, Sone H, Minokoshi Y, Yada T

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis